Please assess the completion status of the following clinical trial:

Trial Title: 24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* outpatient~* signed and dated written informed consent~* 40 years of age or older~* male and female subjects~* COPD diagnosis~* at least 10 pack-year smoking history~* post-albuterol/salbutamol FEV1/FVC ratio of \<0.70 and post-albuterol/salbutamol FEV1 of less than or equal to 70% predicted normal values~* score of greater than or equal to 2 on the Modified Medical Resarch Council Dyspnea Scale (mMRC)~Exclusion Criteria:~* women who are pregnant or lactating or are planning on becoming pregnant during the study~* current diagnosis of asthma~* other respiratory disorders other than COPD~* other diseases/abnormalities that are uncontrolled including cancer not in remission for at least 5 years~* chest x-ray or CT scan with clinically significant abnormalities not believed to be due to COPD~* hypersensitivity to anticholinergics, beta-agonists, lactose/milk protein or magnesium stearate or medical conditions associated with inhaled anticholinergics~* hospitalization for COPD or pneumonia within 12 weeks prior to Visit 1~* lung volume reduction surgery within 12 months prior to Visit 1~* abnormal and clinically significant ECG at Visit 1~* significantly abnormal finding from laboratory tests at Visit 1~* unable to withhold albuterol/salbutamol at least 4 hours prior to spirometry at each visit~* use of depot corticosteroids within 12 weeks of Visit 1~* use of oral or parenteral corticosteroids, antibiotics for lower respiratory tract infection, or cytochrome P450 3A4 inhibitors, within 6 weeks of Visit 1~* use of long-acting beta-agonist (LABA)/inhaled corticosteroid (ICS) product if LABA/ICS therapy is discontinued withing 30 days of Visit 1~* use of ICS at a dose of \>1000mcg/day of fluticasone propionate or equivalent within 30 days of Visit 1~* initiation or discontinuation of ICS within 30 days of Visit 1~* use of tiotropium or roflumilast within 14 days of Visit 1~* use of theophyllines, oral leukotriene inhibitors, long-acting oral beta-agonists, or inhaled long-acting beta-agonists within 48 hours of Visit 1~* short-acting oral beta-agonists within 12 hours of Visit 1~* use of LABA/ICS combination products only if discontinuing LABA therapy and switching to ICS monotherapy within 48 hours of Visit 1 for the LABA component~* use of sodium cromoglycate or nedocromil sodium within 24 hours of Visit 1~* use of inhaled short-acting beta-agonists, inhaled short-acting anticholinergics, or inhaled short-acting anticholinergic/short-acting beta-agonist combination products within 4 hours of Visit 1~* use of any other investigational medication within 30 days or 5 drug half-lives (whichever is longer)~* long-term oxygen therapy prescribed for \>12 hours per day~* regular use of nebulized short-acting bronchodilators~* participation in acute phase of pulmonary rehabilitation program~* known or suspected history of alcohol or drug abse within 2 years prior to Visit 1~* anyone affiliated with the investigator site (e.g., investigator, sub-investigator, study coordinator, employee of a participating investigator or study site, or immediate family member)~* previous exposure to GSK573719, GSK573719/GW642444 combination, GW642444 (vilanterol), or fluticasone furoate/GW642444 combination

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GSK573719/GW642444 125/25 (Type: EXPERIMENTAL): 125/25 mcg once-daily
- GSK573719/GW642444 62.5/25 (Type: EXPERIMENTAL): 62.5/25 mcg once-daily
- GSK573719 (Type: EXPERIMENTAL): 125 mcg once-daily
- tiotropium bromide (Type: ACTIVE_COMPARATOR): 18 mcg once-daily

Based on this trial design, predict the completion outcome and termination type (if applicable).